<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50841">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02444338</url>
  </required_header>
  <id_info>
    <org_study_id>Version No. 3.3</org_study_id>
    <nct_id>NCT02444338</nct_id>
  </id_info>
  <brief_title>A Clinical Evaluation of the Safety and Effectiveness of the MitraClip System in the Treatment of Clinically Significant Functional Mitral Regurgitation</brief_title>
  <acronym>Reshape-HF2</acronym>
  <official_title>A RandomizEd Study of tHe MitrACliP DEvice in Heart Failure Patients With Clinically Significant Functional Mitral Regurgitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Medical Center Goettingen, sponsor of the study</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the safety and effectiveness of the MitraClip System in the treatment of clinically
      significant functional mitral regurgitation in patients with New York Heart Association
      (NYHA) Functional Class II to Class IV chronic heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is designed to provide additional evidence regarding appropriate recommendations
      for use of the MitraClip System for patients with chronic heart failure and clinically
      significant functional mitral regurgitation. Additionally, the trial will collect evidence
      regarding health economics of the MitraClip System for use in this patient population.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cardiovascular (CV) death</measure>
    <time_frame>24 months</time_frame>
    <description>Composite rate of recurrent heart failure hospitalizations and cardiovascular (CV) death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mitral Regurgitation (MR) severity reduction</measure>
    <time_frame>at 12 and 24 months</time_frame>
    <description>Mitral Regurgitation (MR) severity reduction to mild or mild-to-moderate at 12 and 24 months;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6 Minute Walk Test (6MWT)</measure>
    <time_frame>at 6, 12 and 24 months</time_frame>
    <description>Change in 6 Minute Walk Test (6MWT) distance at 6, 12 and 24 months over baseline;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CV hospitalizations and CV death</measure>
    <time_frame>24 months</time_frame>
    <description>Rate of recurrent CV hospitalizations and CV death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL) overall score</measure>
    <time_frame>12 months</time_frame>
    <description>Change in Quality of Life (QoL) overall score, as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ) at 12 months over baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) Functional Class</measure>
    <time_frame>at 6, 12 and 24 months</time_frame>
    <description>Change in New York Heart Association (NYHA) Functional Class over baseline and proportions of patients in NYHA Functional Class I/II at 6, 12 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported Global Assessment (PGA)</measure>
    <time_frame>at 6, 12 and 24 months</time_frame>
    <description>Change in Patient-reported Global Assessment (PGA) of well-being at 6, 12 and 24 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Mitral Valve Insufficiency</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>optimal standard of care therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Device Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MitraClip device plus optimal standard of care therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MitraClip</intervention_name>
    <description>Implantation of the MitraClip System for patients with chronic heart failure.</description>
    <arm_group_label>Device Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard of care</intervention_name>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Device Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Clinically significant functional mitral regurgitation (moderate-to-severe or severe
             MR) as defined by European Association of Echocardiography, within 90 days prior to
             randomization and confirmed by the Echocardiography Core Laboratory Note: The TTE
             must be obtained after the subject has been stabilized on optimal therapy and has
             undergone revascularization and/or CRT, as appropriate

          -  Assessed by the investigator to be on optimal standard of care therapy for heart
             failure, according to current ESC/HFA guidelines with no dose changes of heart
             failure drugs (with the exception of diuretics) during the last 2 weeks immediately
             prior to randomization.

          -  Symptomatic with documented New York Heart Association Class II, III or IV heart
             failure, despite optimal standard of care therapy, within 30 days preceding
             randomization

          -  Minimum of one documented hospitalization (acute care admission or emergency room
             visit) for heart failure within 12 months preceding randomization OR values of 300
             pg/mL for BNP or 1000 pg/mL for NT-proBNP after optimal medical and/or device
             management within 90 days preceding randomization Note: BNP or NT-proBNP must be
             obtained after the subject has been stabilized on optimal therapy and has undergone
             revascularization and/or CRT, as appropriate

          -  Left ventricular ejection fraction (LVEF) of ≥ 15% to ≤ 35% (if in NYHA Functional
             Class II) or of ≥ 15% to ≤ 45% (if in NYHA Functional Class III or IV).

        Note: LVEF needs to be determined by one of the following methods: transthoracic
        echocardiography (TTE), contrast ventriculography, gated blood pool scan, cardiac magnetic
        resonance) within 90 days prior to randomization

        - Patient is ambulatory and able to perform a 6MWT with the only limiting factor(s) being
        due to cardiovascular fitness

        Key Exclusion Criteria:

          -  Mitral regurgitation is primarily due to degenerative disease of the mitral valve
             apparatus (Degenerative MR) as determined by transesophageal echocardiography (TEE).

          -  Status 1 heart transplant or prior orthotropic heart transplantation.

          -  Introduction of a new heart failure drug class within the last 2 weeks prior to
             randomization.

          -  Evidence of acute coronary syndrome, transient ischemic attack or stroke within 90
             days prior to randomization.

          -  Any percutaneous cardiovascular intervention, carotid surgery, cardiovascular
             surgery, or atrial fibrillation ablation within 90 days prior to randomization.

          -  Therapy with or without cardioverter-defibrillator (CRT or CRT-D), or Implantable
             Cardioverter Defibrillator (ICD)) within 90 day prior to randomization, or revision
             of any implanted rhythm management device within 90 days prior to randomization.

          -  Need for any cardiovascular surgery.

          -  Mitral valve surgery is considered the preferred therapeutic option for the subject

          -  Renal replacement therapy

          -  6-Minute Walk Test (6MWT) distance &gt; 475 meters

          -  Mitral Valve Area (MVA) by planimetry &lt; 4.0 cm2; if MVA by planimetry is not
             measurable, pressure half-time measurement is acceptable; MVA must be confirmed by
             the Echocardiography Core Laboratory
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stefan Anker, Prof.</last_name>
    <phone>(+)49 30 450 553 151</phone>
    <email>s.anker@cachexia.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wolfgang Schillinger, Prof.</last_name>
    <phone>(+49)5551/97-12 44</phone>
    <email>medizinischeklinik.northeim@helios-kliniken.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Goettingen</name>
      <address>
        <city>Goettingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Schillinger, Prof.</last_name>
      <phone>(+49)551-39-6372</phone>
    </contact>
    <contact_backup>
      <last_name>Mark Hünlich, Dr.</last_name>
      <phone>(+49)551-39-6310</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raffi Bekeredjan, Prof.</last_name>
      <phone>(+49)6221-5639097</phone>
    </contact>
    <contact_backup>
      <last_name>Lutz Frankenstein, Dr.</last_name>
      <phone>(+49)6221-5638895</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph Stefan von Bardeleben, Dr.</last_name>
      <phone>(+49)6131-17-2892</phone>
    </contact>
    <contact_backup>
      <last_name>Tommaso Gori, Prof.</last_name>
      <phone>(+49)6131-17-2829</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 30, 2016</lastchanged_date>
  <firstreceived_date>May 12, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
